Sale!

CEP290 Gene Bardet-Biedl Syndrome Type 14 Genetic Test

4,400 د.إ

-21%

The CEP290 Gene Bardet-Biedl Syndrome Type 14 Genetic Test is a specialized diagnostic procedure offered by DNA Labs UAE, designed to identify mutations in the CEP290 gene, which are associated with Bardet-Biedl Syndrome Type 14 (BBS14). This syndrome is a complex genetic disorder that affects multiple body systems, leading to symptoms such as vision loss, kidney dysfunction, obesity, learning disabilities, and polydactyly (extra fingers or toes). The test is crucial for early diagnosis, enabling timely intervention and management of the condition.

At DNA Labs UAE, the test is conducted with precision and care, utilizing advanced genetic sequencing techniques to accurately detect the presence of mutations in the CEP290 gene. The cost of the test is 4400 AED, reflecting the sophisticated technology and expertise required to carry out the analysis. Early detection through this genetic test can significantly impact the quality of life for individuals with Bardet-Biedl Syndrome Type 14, offering insights into potential treatments and preventive measures for associated complications.

Home  Sample collection service available

  • 100% accuaret DNA Results
  • Ranked as Most trusted Genetic DNA Lab
Guaranteed Safe Checkout

CEP290 Gene Bardet-Biedl syndrome type 14 Genetic Test

Cost: 4400.0 AED

Test Components:

  • Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery:

3 to 4 Weeks

Method:

NGS Technology

Test Type:

Ophthalmology Disorders

Doctor:

Ophthalmologist

Test Department:

Genetics

Pre Test Information:

Clinical History of Patient who is going for CEP290 Gene Bardet-Biedl syndrome type 14 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CEP290 Gene Bardet-Biedl syndrome type 14 NGS Genetic DNA Test gene CEP290

Test Details:

The CEP290 gene is associated with Bardet-Biedl syndrome type 14, a rare genetic disorder that affects multiple parts of the body. This condition is characterized by obesity, vision loss, kidney abnormalities, and other symptoms.

NGS (Next Generation Sequencing) genetic testing can be used to analyze the CEP290 gene and identify any mutations or variations that may be causing Bardet-Biedl syndrome type 14. This type of testing is highly accurate and can detect even small changes in the genetic code.

If a mutation or variation is found in the CEP290 gene, individuals may be diagnosed with Bardet-Biedl syndrome type 14 and can receive appropriate medical care and genetic counseling. Testing may also be recommended for family members of affected individuals to determine their risk of developing the condition.

Test Name CEP290 Gene Bardet-Biedl syndrome type 14 Genetic Test
Components
Price 4400.0 AED
Sample Condition Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery 3 to 4 Weeks
Method NGS Technology
Test type Ophthalmology Disorders
Doctor Ophthalmologist
Test Department: Genetics
Pre Test Information Clinical History of Patient who is going for CEP290 Gene Bardet-Biedl syndrome type 14 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with CEP290 Gene Bardet-Biedl syndrome type 14 NGS Genetic DNA Test gene CEP290
Test Details

The CEP290 gene is associated with Bardet-Biedl syndrome type 14, a rare genetic disorder that affects multiple parts of the body. This condition is characterized by obesity, vision loss, kidney abnormalities, and other symptoms.

NGS (Next Generation Sequencing) genetic testing can be used to analyze the CEP290 gene and identify any mutations or variations that may be causing Bardet-Biedl syndrome type 14. This type of testing is highly accurate and can detect even small changes in the genetic code.

If a mutation or variation is found in the CEP290 gene, individuals may be diagnosed with Bardet-Biedl syndrome type 14 and can receive appropriate medical care and genetic counseling. Testing may also be recommended for family members of affected individuals to determine their risk of developing the condition.